Prior Art Litigation Search in Lyon.

Prior art search Lyon work is life-sciences and chemistry work first, because the patents fought over around this city protect vaccines, in-vitro diagnostic assays, veterinary biologics, drug formulations and specialty chemistry rather than consumer electronics. Lyon anchors one of Europe’s densest health clusters, built around Sanofi Pasteur’s vaccine campus at Marcy-l’Étoile, bioMérieux in in-vitro diagnostics, Boehringer Ingelheim’s animal-health operations that grew out of Mérial, and the Lyonbiopôle competitiveness cluster, with a large chemicals and cleantech corridor, the Vallée de la chimie, running south along the Rhône. When one of those patents is asserted, the invalidity fight runs through the Unified Patent Court, a national nullity action before the Tribunal judiciaire de Paris, or a nine-month opposition at the European Patent Office. In biotech, pharma and chemistry disputes the reference that actually kills a claim is rarely another patent, but a journal article, a clinical-trial disclosure, a deposited sequence or an earlier formulation. PerspireIP builds that non-patent-literature record on the compressed clocks these proceedings impose.

Why prior art search Lyon cases turn on non-patent literature

Every prior art search Lyon matter begins with the same question: where does the disclosure that defeats this claim actually live? In vaccine, diagnostic, antibody and small-molecule fields the state of the art moves through peer-reviewed journals, congress abstracts and regulatory filings far faster than through the patent register, so a search confined to patent databases misses the references that decide these cases. The killer art is almost always non-patent literature.

The reason is structural. Scientists at Sanofi Pasteur, bioMérieux and the hospital and university laboratories around Lyon publish in journals indexed by PubMed and Embase, present at immunology, virology and microbiology congresses, and disclose assay parameters, adjuvant systems and dosing regimens in clinical-trial registries and marketing-authorisation dossiers, frequently at the same time as, or before, a patent is filed. That public trail is exactly what anticipates or renders obvious a later claim.

PerspireIP treats non-patent literature as the primary corpus rather than an afterthought, then charts each reference claim element by claim element so counsel receives a filing-ready invalidity record instead of a raw list of hits.

Lyon’s life-sciences and chemistry base: where the art comes from

Lyon is France’s leading life-sciences region and one of the largest health clusters in Europe. Sanofi Pasteur, the vaccines business of Sanofi, runs its historic worldwide operations from Marcy-l’Étoile on the western edge of the city, while bioMérieux, founded in Lyon, is a global leader in in-vitro diagnostics and microbiology testing.

Animal health is a second pillar. The veterinary business that began as Mérial, now part of Boehringer Ingelheim, keeps several sites in the Lyon area, including one of the world’s largest veterinary-vaccine production and research centres at Saint-Priest. These companies, together with roughly 180 life-science SMEs and seventeen research centres, are federated by the Lyonbiopôle competitiveness cluster, a recognised world centre for infectious disease, immunology, vaccines and diagnostics.

South of the city, the Vallée de la chimie concentrates specialty chemicals, energy and cleantech producers along the Rhône, with more than ten thousand direct jobs. For a defendant that density cuts both ways: the asserted patent often sits in a crowded field where earlier work by a competitor, a public research consortium or the patentee’s own team is already on the public record and ready to be turned into an invalidity theory.

The killer references: journals, clinical disclosures, sequences and formulations

In a life-sciences or chemistry matter the strongest references usually come from a predictable set of sources that a patent-only search never reaches. Getting to them, and proving when each one became public, is the real work.

• Peer-reviewed journals indexed in PubMed and MEDLINE, Embase and the applied-chemistry literature
• Congress abstracts and posters from immunology, virology, microbiology and diagnostics meetings
• Clinical-trial registries and public regulatory disclosures, including EMA and ANSM dossiers, FDA filings and EPARs
• Deposited nucleic-acid and protein sequences in GenBank, EMBL-EBI and UniProt, plus antibody and hybridoma disclosures
• Earlier formulation, adjuvant, assay-protocol and manufacturing-process disclosures, including doctoral theses and preprints

The evidentiary challenge is public availability. A poster or a thesis only counts as prior art if it was accessible to the interested public before the patent’s priority or filing date, so we pin every reference to a verifiable date using journal publication records, congress programmes, registry timestamps and library accession stamps rather than a bare citation.

Three routes to invalidate a patent asserted against a Lyon defendant

A Lyon defendant facing an asserted European patent typically has three distinct forums in which to attack validity, and each carries its own rules, clocks and evidentiary limits. Choosing among them is a strategic decision your litigation counsel makes, but all three draw on the same underlying prior-art record.

• UPC revocation. A central revocation action or a revocation counterclaim before the Unified Patent Court, whose ruling takes effect across all participating member states at once.
• French national nullity. An invalidity action or defence before the Tribunal judiciaire de Paris, which holds exclusive national jurisdiction over French patents and the French parts of unopted European bundles.
• EPO opposition. A centralised opposition at the European Patent Office, available only within nine months of the mention of grant, deciding validity for every state where the patent was validated.

Because opposition and revocation can proceed in parallel, and because a full patent invalidation theory has to survive whichever forum is chosen, we build one evidence base that all three routes can use rather than searching the same field three times. That single prior art search Lyon counsel commission then feeds an EPO opposition brief, a UPC revocation annex and a French nullity writ without duplicated cost.

UPC central division: Milan for vaccines, Munich for chemistry, Paris for SPCs

The subject matter of a UPC central-division case is allocated by the technical field of the patent, and for Lyon that allocation looks very different from a semiconductor city’s. Following the reallocation of the former London workload, the Milan seat handles IPC section A (human necessities), which covers medical, vaccine, diagnostic and veterinary subject matter, while the Munich seat takes IPC section C (chemistry and metallurgy), including many pharmaceuticals, peptides, nucleic acids and genetic-engineering inventions.

So a central revocation of a typical Lyon vaccine, immunoassay or antibody patent is most often heard in Milan, and a specialty-chemistry or active-ingredient patent in Munich, not in Paris. The Paris central seat keeps IPC sections B, D, E, G and H, and it holds one nuance that matters enormously to pharma defendants: exclusive competence over supplementary protection certificates, the instruments that extend patent-like protection on authorised medicines.

Infringement, by contrast, is usually heard where the defendant sits, so a Lyon-domiciled defendant can expect an infringement action, and any revocation counterclaim, before the UPC’s Paris local division. UPC proceedings are heavily front-loaded: the revocation action or counterclaim must set out the full invalidity case, with the prior art annexed, at the first written stage, so the searching cannot wait for disclosure.

Much of the decisive literature for a Lyon biologic or chemistry patent is English-language journal and congress material, even when the proceedings run in French, German or Italian, so translations and public-availability proof have to be assembled up front. Because the court can hear infringement and validity together and decide quickly, the strength of the prior art assembled before the first exchange often shapes settlement leverage more than any later procedural move.

French national nullity before the Tribunal judiciaire de Paris

Outside the Unified Patent Court, France centralises all patent litigation in a single venue. Under the Intellectual Property Code, the Tribunal judiciaire de Paris has exclusive national jurisdiction over patent validity and infringement, and every French patent dispute is routed to its dedicated intellectual-property chambers wherever the defendant is based. That is why a Lyon company’s case is heard in Paris rather than locally, with appeals to the Paris Court of Appeal.

This route stays relevant even in the UPC era. A patentee may opt a classical European patent out of the UPC system, leaving its French part to be invalidated only through a national nullity action in Paris, and French patents granted by the INPI can be challenged only there. National nullity also reaches the French designation, and any French supplementary protection certificate, specifically.

Whether the fight is national or unitary, the invalidity case rests on the same biological, clinical and chemical literature. We supply that record in a form French counsel can annex to a nullity writ or to invalidity submissions, with each reference translated where needed and mapped to the claims it defeats.

How PerspireIP builds a Lyon invalidity record

We start from the claims, not the keywords. A prior art search Lyon defendant relies on has to be organised the way a UPC revocation annex, an opposition notice or a French nullity writ needs it, so each asserted claim is broken into elements and each element mapped to the art that reads on it.

• Element-by-element claim charts with anticipation and obviousness mapping
• Deep non-patent-literature retrieval across PubMed and MEDLINE, Embase, congress proceedings and the chemistry literature
• Sequence, formulation, adjuvant and assay-protocol evidence for real-world biological and chemical disclosure
• Regulatory and clinical-trial disclosure analysis, including EMA and ANSM dossiers and trial-registry entries
• Public-availability timelines pinning every reference to a verifiable pre-priority date

We work under confidentiality as a search partner to your litigation counsel and patent attorneys, to the court and office deadlines that govern each forum. The work often runs alongside a broader prior art litigation search or a defensive patent infringement analysis, so validity and non-infringement positions come from one consistent evidence base.

We are candid about what we find. A search that surfaces only weak art is worth knowing early, while settlement, design-around and licensing options are still open and inexpensive, and our memos grade references honestly rather than overselling a case a defendant is about to bet a product line on.

IP Landscape & Resources in Lyon

Key intellectual-property authorities and venues relevant to Lyon:

• INPI (Institut national de la propriété industrielle) — the French national office that grants and registers French patents and maintains the national patent register
• Tribunal judiciaire de Paris — holds exclusive national jurisdiction over French patent validity and infringement actions
• Unified Patent Court (UPC) — its Milan seat hears revocation for human-necessities patents (IPC A), Munich for chemistry (IPC C), Paris for SPCs
• European Patent Office (EPO) — grants European patents and hears centralised oppositions filed within nine months of grant

Request a Prior Art Search in Lyon

Explore related PerspireIP services: Prior Art Litigation Search · Patent Invalidation · Patent Infringement Analysis.

Frequently Asked Questions